SORD Antibody

What is SORD and what cellular functions does it perform?

SORD (Sorbitol Dehydrogenase) is an enzyme encoded by the SORD gene that belongs to the zinc-containing alcohol dehydrogenase family. In humans, the canonical protein consists of 357 amino acid residues with a molecular weight of 38.3 kDa . It primarily localizes to the mitochondria and cellular membranes, with alternative splicing yielding two different isoforms . SORD functions as a polyol dehydrogenase that catalyzes the reversible NAD(+)-dependent oxidation of various sugar alcohols, particularly the conversion of sorbitol to fructose in the polyol pathway . This enzyme is notably expressed in the liver and plays a significant role in the sorbitol pathway, which has been implicated in the development of diabetic complications .

What are the common applications of SORD antibodies in research?

SORD antibodies are utilized in multiple experimental applications:

These applications enable researchers to investigate SORD protein expression, localization, and interactions in various experimental contexts .

How should I select the appropriate SORD antibody for my experiment?

Selection should be based on multiple factors:

• Target species: Ensure the antibody reacts with your experimental model. Available antibodies show reactivity with human, mouse, rat, cow, sheep, dog, rabbit, pig, guinea pig, and horse samples, with varying degrees of homology (e.g., human: 100%, mouse: 79%, rat: 93%) .

• Specific epitope recognition: Antibodies targeting different regions (N-terminal, internal region, C-terminal) are available. The epitope choice depends on accessibility in your application and whether specific domains need to be targeted .

• Clonality:

  • Monoclonal antibodies (e.g., clone 12B10G2, 4D3, 1C2) provide consistent results with high specificity but might recognize only a single epitope .

  • Polyclonal antibodies offer broader epitope recognition but may have batch-to-batch variation .

• Validated applications: Verify the antibody has been tested in your application of interest with supporting data .

How can SORD antibodies be used to investigate the polyol pathway in diabetic complications?

The polyol pathway, involving SORD and aldose reductase, plays a crucial role in diabetic complications . When investigating this pathway:

• Dual marker studies: Use antibodies against both SORD and aldose reductase to evaluate the relative expression and activation of both enzymes.

• Tissue-specific analyses: Focus on tissues most affected in diabetes (retina, kidney, peripheral nerves). SORD antibodies have been validated in kidney tissues, showing distinct expression patterns in normal versus pathological states .

• Subcellular fractionation: Combine with mitochondrial markers to assess SORD's role in mitochondrial dysfunction during hyperglycemia.

• Phosphorylation status: Use phospho-specific antibodies alongside total SORD antibodies to assess regulation under diabetic conditions.

• Intervention studies: Use SORD antibodies to measure protein levels after pharmacological interventions targeting the polyol pathway.

What considerations should be made when using SORD antibodies in cross-species studies?

Cross-species reactivity varies significantly among SORD antibodies:

When conducting cross-species studies:

• Perform preliminary validation in each species

• Consider using conserved epitope regions (check sequence alignment)

• Adjust antibody concentration for different species

• Include appropriate positive controls from each species

• Verify specificity using knockout/knockdown models when available

How can computational approaches enhance SORD antibody design and selection?

Recent advances in computational modeling offer new opportunities for SORD antibody research:

• Diffusion-based generative models: Novel computational techniques can jointly model sequences and structures of complementarity-determining regions (CDRs) of antibodies, potentially applicable to designing SORD-targeting antibodies with higher specificity .

• Large language models (LLMs): MIT researchers have developed computational techniques that allow LLMs to predict antibody structures more accurately, which could be applied to enhance SORD antibody design .

• Pre-trained antibody models: Models like PALM-H3 and A2Binder can aid in pairing antigen epitope sequences with antibody sequences to predict binding specificity and affinity, potentially applicable to SORD antigen-antibody interactions .

• Equivariant neural networks: These networks can model both position and orientation of amino acids, crucial for understanding SORD epitope accessibility and antibody binding sites .

• Optimization algorithms: Computational approaches now enable optimization of existing antibodies to increase binding affinity to specific targets .

What are the optimal protocols for SORD detection in immunohistochemistry?

Based on validated protocols:

• Tissue preparation: Paraffin-embedded sections of tissues known to express SORD (liver, kidney) are recommended .

• Antigen retrieval: Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) has been validated for SORD detection .

• Blocking: 10% goat serum is effective for reducing background signals .

• Primary antibody incubation:

  • Concentration: 2 μg/ml of mouse anti-SORD antibody

  • Incubation: Overnight at 4°C for optimal results

• Secondary antibody: Peroxidase Conjugated Goat Anti-mouse IgG (30 minutes at 37°C) .

• Detection system: HRP-conjugated detection system with DAB as chromogen provides clear visualization .

• Controls: Include positive controls (liver cancer, renal clear cell carcinoma) where SORD expression has been verified .

What are the key considerations for optimizing Western blotting with SORD antibodies?

Optimize Western blotting by considering:

• Sample preparation: Preparation from tissues with high SORD expression (liver, kidney) or cell lines (HepG2, LNCaP, Jurkat) .

• Protein loading: 20-50 μg of total protein per lane is typically sufficient for SORD detection.

• Antibody dilution: Wide range depending on antibody sensitivity:

  • Monoclonal: 1:5000-1:50000 (for high-sensitivity antibodies like 67625-1-Ig)

  • Polyclonal: Typically 1:1000-1:5000

• Expected band size: 38 kDa is the observed molecular weight for SORD .

• Positive controls: Include validated cell lines (LNCaP, HSC-T6, PC-12, NIH/3T3, HeLa, HepG2, Jurkat, K-562) .

• Secondary antibody: Match to host species of primary antibody (anti-mouse or anti-rabbit).

• Validation: Validate specificity using knockdown/knockout samples when possible .

What are common issues in SORD antibody applications and how can they be resolved?

How should SORD antibody specificity be validated?

Comprehensive validation includes:

• Western blot at the expected molecular weight (38 kDa) .

• Knockout/knockdown validation: Compare signal in wild-type vs. SORD-deficient samples .

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding.

• Cross-species validation: Test reactivity in species with known sequence homology (human: 100%, mouse: 79%, rat: 93%) .

• Multiple application concordance: Verify that results are consistent across different applications (WB, IHC, IF).

• Positive and negative tissue controls: Compare tissues known to express high levels of SORD (liver) with those with low expression .

How are AI-based approaches transforming SORD antibody research?

Recent advances in AI are creating new opportunities:

• Diffusion probabilistic models: These models can generate antibodies targeting specific antigen structures, potentially applicable to creating highly specific SORD antibodies .

• Pre-trained large language models: Systems like Roformer can be trained on antibody sequences to improve prediction of SORD-antibody interactions .

• Structure-aware models: Computational approaches now consider both the position and orientation of amino acids, crucial for modeling SORD binding sites .

• Antibody optimization: Rather than de novo design, AI can optimize existing antibodies to increase binding affinity to SORD epitopes .

• Affinity prediction: Models like A2Binder can predict binding affinity between SORD epitopes and antibody candidates, reducing the need for extensive experimental screening .

What are the future directions for SORD antibody applications in research?

Future research will likely focus on:

• Single-cell analysis: Applying SORD antibodies in single-cell proteomics to understand cell-specific expression patterns.

• Multiplex imaging: Combining SORD antibodies with other markers in spatial proteomics to understand pathway interactions.

• Therapeutic development: Using high-specificity antibodies to modulate SORD activity in diabetic complications and other pathologies.

• Structural biology integration: Combining antibody detection with structural biology techniques to understand conformational changes in SORD.

• Computational design improvement: Utilizing diffusion models and equivariant neural networks to design antibodies with unprecedented specificity and affinity to SORD .